Moleculin Biotech Completes Patient Enrollment In Part A Of Its Pivotal Phase 2/3 MIRACLE Study Of Annamycin In Combination With Cytarabine To Treat Adults With Relapsed Or Refractory Acute Myeloid Leukemia

Moleculin Biotech, Inc. (NASDAQ: MBRX) has completed enrollment in Part A of its pivotal Phase 2/3 MIRACLE trial, with 89 subjects enrolled for the study of Annamycin in combination with cytarabine for treating adults with relapsed or refractory acute myeloid leukemia. An additional subject is currently in screening, and the company anticipates a comprehensive data readout in the first quarter of 2027. The rapid enrollment highlights the significant unmet need in this patient population and the engagement from clinical sites.